|
|
Method of inhibiting microorganisms in pulp and paper industry Invention can be used in the pulp and paper industry for inhibition and control of microbial growth in the technical and circulating waters. For implementing the method, in the water to be treated a preliminary prepared mixture of bromochlorodimethylhydantoin and sodium hypochlorite is added, with the concentration of bromochlorodimethylhydantoin of 0.1 to 7.5 g/l, and their ratio in terms of active chlorine from 1:15 to 15:1. |
|
|
Conjugates for prevention or treatment of nicotine addiction Invention relates to conjugates, in particular presented is nicotine hapten-carrier of formula (III): W represents -O- and is in position 5 of pyridine ring; -(spacer)- represents C1-C8alkylene group, C3-C10cycloalkylene group or C1-C12alkylene group, interrupted by 1-4 oxygen atoms and possibly interrupted by group -N(H)C(O)-; X* represents -NH- or -S-; m stands for 1; n stands for integer number from 1 to 1000; and Y represents possibly modified carrier protein, selected from bacterial anatoxins, immunogenic substances, viruses, virus-like particles, protein complexes, proteins, polypeptides, liposomes and immunostimulating complexes, which can be used for preparation of vaccines for treatment and/or prevention of nicotine dependence. |
|
Method for detecting gastric mucosa erosions in children with juvenile arthritis Method involves an integral assessment of patient's complaints, previous medical history and laboratory parameters, in points: absence of abdominal pain - 4 points, patient's being male - 4 points, patient's age older than 12 years - 4 points, presence of a combined anti-inflammatory therapy - 4 points, length of a combined therapy from 1 to 3 years - 3 points, systemic form of juvenile arthritis - 2 points, absence of parietal cell anti-H+K+/ATPase auto-antibodies - 4 points, positive result of the Colon View Hb/Hp test - 4 points, pepsinogen II above the norm - 3 points, pepsinogen I/pepsinogen II - 3 points, gastrin-17 above the norm - 2 points. If the total score is 27 points or more, the gastric mucosa erosions are detected in the children suffering from juvenile arthritis. |
|
Group of the inventions relates to field of delivery of useful agents in consumer goods, namely deals with encapsulate, containing envelope, based on cross-linked polymer, and core, containing material, selected from the group, consisting of fragrance, silicon, biocontrol agent, antimicrobial agent, flavour, warming or cooling agent, medication, sunscreen preparation and their mixtures. Said envelope additionally contains fragment, sensitive to electromagnetic radiation, selected from the group, consisting of visible light, ultraviolet radiation and their mixtures, provided by monomer of structure: |
|
Cosmetic composition in form of water-in-oil emulsion Invention relates to cosmetic industry, namely represents cosmetic preparation in form of water-in-oil emulsion. Cosmetic preparation in form of water-in-oil emulsion in accordance with invention is characterised by the fact that it contains the following components (A) - (D): (A) from 0.5 to 10 wt % of hydrogenated polyisobutene, (B) oil, containing component (b1): (b1) volatile oil, which has low compatibility with component (A), (C) emulsifier and (D) from 60 to 90 wt % of water component, where content of component (b1) constitutes from 45 to 85% of weight of components (A) and (B). |
|
Method for producing dry refined extract of european bugleweed herb exhibiting thyreotropic action Presented method involves extracting ground European bugleweed herb in 30-50% aqueous ethanol, evaporating the extract until alcohol is removed completely (2-3% of the initial volume), diluting with distilled water 1:4, processing in chloroform, evaporating an aqueous form after separating chloroform to an amount equal to that produced after the aqueous-alcoholic extract evaporated, drying the residue in a vacuum drying chamber at 60±2°C and grinding. |
|
Method for reducing isoniazid neurotoxicity experimentally To reduce isoniazid neurotoxicity experimentally, the treatment with isoniazid is combined with administering vitamin B6 and taurine in isoniazid:vitamin B6:taurine ratio - 200:1.3-3.9:255. |
|
Composition for oral care with corrected taste Invention is a composition for oral care, comprising: a) taste correcting component in a concentration of from 0.5 to 2.5 wt %, comprising: more than 29.5% by weight of L-menthol; more than 4.5% by weight of N-ethyl-para-menthane-3-carboxamide; less than 14.5% by weight of anethole; more than 0.1% by weight of cinnamic aldehyde; more than 0.1% by weight of eugenol; more than 0.5% by weight of eucalyptol; less than 40.5% by weight of peppermint oil; less than 5.5% by weight of spearmint oil; and more than 4.5% by weight of field mint oil; b) one or more zinc salts selected from: zinc oxide; zinc sulphate; zinc chloride; zinc citrate; zinc lactate; zinc gluconate; zinc malate; zinc tartrate; zinc carbonate; zinc phosphate; and combinations of two or more thereof, the total concentration of zinc salts is from 0.01 to 5% by weight of the weight of the composition, and c) an orally acceptable carrier. |
|
|
Agent for treatment of acute gastrointestinal diseases of newborn lambs Preparation comprises in its structure the following components, wt %: sodium acetate - 45, flour of dried rhizome of leather bergenia Bergenia crassifolia - 25, dry extract of oak bark - 25, zinaprim - 2.5, metronidazole - 2.5. |
|
Method for integrated rehabilitation treatment of children with post-traumatic elbow contracture Treating children with post-traumatic elbow contracture is ensured by daily massage of the upper extremity, applications of a heating agent on the joint area, electrophoresis of potassium iodide and lidase at a current density of 0.01-0.07 mA/cm2, for 5-15 minutes, and kinesitherapy. The applicator is Tereclit clay heated to 36-42°C and covering the elbow joint area and spastic muscles for 8-15 minutes. Thereafter, 30-40 minutes later, the clay therapy is followed by doing 10-15-minute long passive motions by means of a mechanotherapeutic device. The procedure length and number are specified on the basis of the child's age and initial functional health of the elbow joint. |
|
Bacteriophage-containing room deodorant Room deodorant contains a concentrate of selected high-avidity bacteriophages of the species Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Salmonella enterica, Proteus mirabilis, Proteus vulgaris, Klebsiella pneumoniae, Yersinia pseudotuberculosis, Yersinia enterocolitica, Pseudomonas aeruginosa. The concentrate of the above bacteriophages possesses Appelman's lytic activity 10-8 of each bacteriophage. The bacteriophages are grown on a dense medium and purified by ultrafiltration. The above agent contains a perfume compound and isothiozolinone-based preserving agents not reducing bacteriophage activity. Bacteria nutrients are absent. |
|
Invention relates to medicine and represents anaesthetic composition, which contains neuroactive steroidal anaesthetic, composed with cyclodextrin, where neuroactive steroidal anaesthetic is selected from the group, consisting of alphadolone, alphaxalone and pregnanolone. Cyclodextrin represents (7) sulphobutyl ether of beta-cyclodextrin. Molar ratio of steroidal anaesthetic to cyclodextrin is within the interval from 1:1.6 to 1:2.5, except alphadolone, where it constitutes from 1:2 to 1:2.5. Invention also relates to methods for induction of anaesthesia and sedative effect by means of composition. |
|
Invention relates to photochemotherapy and photodynamic therapy, namely to application of pharmaceutically acceptable salt of amphiphilic photosensitising preparation in method of photochemical internalisation, where said salt possesses water solubility of at least 30 mg/ml and is selected from diethanolamine salt TPCS2a, diethanolamine salt TPPS2a, ethanolamine salt TPPS2a and triethanolamine salt TPPS2a. |
|
|
Easily dosed solid medicinal preparation Invention refers to chemical-pharmaceutical industry and represents a composition for coating an orally administered medicinal preparation, containing: a first thickening agent specified in a group consisting of carboxyvinyl polymer and sodium alginate; a polyvalent metal compound representing a pharmaceutically acceptable salt of polyvalent metal, e.g. calcium, magnesium, aluminium and zinc; at least one type of a second thickening agent specified in a group consisting of xanthum gum, guar gum and sodium alginate; provided the first thickening agent is sodium alginate, the second thickening agent is other than sodium alginate; the composition also containing hydroxypropylmethyl cellulose and sugar or sugar alcohol having a solubility of 30 g or more in 100 g of water at 20°C. |
|
|
Medication is obtained by method, including cultivation of mesenchymal stromal cells of human adipose tissue (MSC AT) of 2-5 passage in growth medium until concentration of total protein in medium 3-4 mg/ml is achieved. Selection and purification of culture medium and its concentration until initial volume of purified culture medium is reduced 9-11 times are carried out with obtaining sterile concentrate, with its further lyophilisation. Medication contains products of human MSC secretion, including key growth factors: FGF basic in concentration from 2 to 4 pg/ml, HGF in concentration from 40 to 80 pg/ml, VEGF in concentration from 200 to 800 pg/ml, angiopoietin-1 in concentration from 0.5 to 10.0 pg/ml, determined by method of enzyme immunoassay with reduction of lyophilisate in 100 ml of sterile physiological solution. Growth medium contains solution of AdvanceSTEM Cell Culture Media, solution of antibiotics Penicillin-Streptomycin and additives AdvanceSTEM Stem Cell Growth Supplement with the following component ratio, vol %: AdvanceSTEM Cell Culture Media - 85-95, solution of antibiotics Penicillin-Streptomycin - 0.95-1.05, additives to growth medium AdvanceSTEM Stem Cell Growth Supplement - 9.5-10.5. Group of inventions also relate to method of treating burns and wounds. |
|
Reinforced resorbable synthetic matrix for haemostatic applications Group of inventions relates to a reinforced resorbable blood clotting agent containing at least one haemostatic agent in one layer of nonwoven synthetic material consisting of a mixture of pressed fibre staples of a polyglycolide and polylactide copolymer and a polydioxanone in weight ratio of 80:20 to 60:40, with density of 50 to 200 mg/cm3. |
|
|
Method for preventing and treating benign prostatic hyperplasia Invention refers to medicine, namely urology, namely to a method for preventing and treating benign prostatic hyperplasia (BPH). The method for preventing and treating benign prostatic hyperplasia in males involves administering an agent based on a pro-vitamin pine concentrate. |
|
Method of quality assessment of powder of canned deer velvet antlers For pre-sailing quality assessment of the velvet antler the powder quality assessment is carried out in three factors: the powder colour, ash content and the extension factor corresponding to 1, 2 and 3 class of velvet antler powder. |
|
Group of inventions relates to field of stabilisation of folliculostimulating hormone (FSH) liquid compositions. Claimed is application of sodium sulphate or its combination with sodium chloride for stabilisation of liquid FSH composition and method for restricting FSH tendency to dissociation in liquid composition. FSH loses biological activity in case of dissociation of non-covalently bound monomers. |
|
Lyophilised preparation of botulinum toxin Invention refers to a pharmaceutical lyophilised preparation of botulinum toxin. The pharmaceutical lyophilised preparation contains: botulinum toxin, Polysorbate, and methionine; Polysorbate is taken in an amount of 0.01 to 2 mg per 100 units of botulinum toxin, and methionine is taken in an amount of 0.01 to 10 mg per 100 units of botulinum toxin; and one or more components specified in a group consisting of sugar in an amount of 0.1 to 50 mg per 100 units of botulinum toxin, sugar alcohol in an amount of 0.1 to 50 mg per 100 units of botulinum toxin and an ionic compound in an amount of 0.1 to 10 mg per 100 units of botulinum toxin. |
|
|
Peroxide solution and set for disinfection of contact lenses Group of inventions relates to medicine, namely to disinfecting systems for medical devices. For this purpose hydrogen peroxide solution is used for disinfection of contact lenses. To increase effective time of activity of hydrogen peroxide solution to 6 hours and its residual concentration lower than 100 ppm catalyst is used. Components for disinfection of contact lenses are placed into device, which includes a) container for water solution of hydrogen peroxide, containing effective quantity of vinylpyrrolidone copolymers and b) container, which contains disk, representing substrate with catalytic covering, with disk having to be completely submerged into hydrogen peroxide solution. Catalyst application provides increased concentration of oxygen peroxide by at least 80%. |
|
Medicinal agent for preventing and/or treating hepatocellular carcinoma Invention refers to pharmaceutical industry and represents a pharmaceutical agent applicable for post-treatment recurrent hepatocellular carcinoma inhibition and containing peretinoin combined with L-isoleucine, L-leucine and L-valine. |
|
Topical agent for treating joint and soft-tissue disorders Invention refers to chemical-pharmaceutical industry and represents a topical agent for treating joint and soft-tissue disorders, containing a non-steroidal anti-inflammatory agent, which is presented by meloxicam, and a pharmaceutically acceptable base containing a mixture of water, trometamol, N-methylpyrrolidone and ethanol, wherein meloxicam is taken in the form of a true solution with the base components. |
|
Invention refers to chemical-pharmaceutical industry and represents an injection solution for treating viral diseases specified in H1N1, H3N2, H5N1 influenza, tick-borne encephalitis and West Nile fever, containing triazavirin in an amount of 0.05-4.0 wt %, additives in an amount of 0.1-30.0 wt % and water up to 100 wt %. |
|
Tacrolimus for improved treatment of patients with grafts What is described is a method for providing an immunosuppressive once-a-day treatment of a patient, preferentially a patient with a renal or hepatic graft by administering an extended-release oral tablet. The tablet contains 0.1 to 15 mg of tacrolimus, hydroxypropyl metylcellulose, lactose monohydrate, polyethylene glycol 6000, poloxamer 188, magnesium stearate, tartaric acid, butylated hydroxytoluene and dimethicone 350. |
|
Group of inventions refers to medicine and concerns use of cathepsin H to identify compounds modulating neuropathic pain. The group of inventions also concerns using a cell providing heterologous expression of cathepsin H or its functional fragment, to identify the compounds modulating neuropathic pain; use of a cathepsin H knock-out cell to identify or analyse the compounds modulating neuropathic pain; a method for identifying or analysing the compounds modulating and/or preventing neuropathic pain. |
|
Method of treating synovitis and/or synovial cysts Invention refers to medicine, particularly a method of treating synovitis and/or synovial cysts. The method of treating synovitis and/or synovial cysts, consisting in puncturing an articular cavity and/or cyst cavity, aspirating its contents and introducing the biological preparation Sextaphage into the above cavity in a smaller amount than that of the aspirated effusion; the procedure is repeated 2-5 times during at least two weeks every 3-4 days. |
|
|
Composition and method of producing air fragrance Air fragrance contains an odorant, polyvinyl alcohol, carboxymethyl cellulose, oxyethylated alkyl phenol, glycerine and glyoxal, with the following ratio of components, wt %: polyvinyl alcohol - 5.0-7.0; carboxymethyl cellulose - 0.5-1.0; oxyethylated alkyl phenol AF9-12 - 0.05-0.1; odorant - 5.0-10.0; glycerine - 10.0-45.0; glyoxal - 2.0-12.0; water - the balance. The group of inventions also relates to a method of producing the air fragrance, which includes the preparation of an aqueous solution of polyvinyl alcohol with the addition of an odorant and the said additives and then freezing at a temperature of -20°C for 20 hours and thawing at room temperature of +25°C for 4 hours. |
|
Medication for treating and prevention of alcoholism Claimed is application of glycine conjugate, immobilised on particles of detonation nanodiamond with size 2-10 nm, as anti-alcohol medication for treatment and prevention of alcoholism. |
|
Tabletted dietary supplement containing iodine and selenium Tabletted dietary supplement containing iodine and selenium, the rest - other substances, contains iodine and selenium in mass ratio approximately 2:1 in the iodine content of 100-400 mcg. |
|
|
Method of treating patients with rheumatoid arthritis Invention represents a method of treating patients with rheumatoid arthritis, involving the simultaneous integrated use of medicinal preparations and a laser therapy, differing by the fact that a baseline anti-inflammatory preparation is methotrexat taken orally once a week in a dose of 15 mg, and folic acid is also prescribed in a dose of 5 mg; movalis is injected intramuscularly for 5-10 days in a dose of 15 mg, which is combined with 7-10 procedures of intravenous blood laser irradiation by means of a KL-VLOK radiation head at wave length 635 nm, disposable light guide end power 1.5 mW, exposure length 15 minutes alternated with a KL-VLOK 365 c radiation head at wave length 365 nm, disposable light guide end power 1.0 mW, and exposure length 5 minutes. |
|
|
Dental compositions containing ethylene-unsaturated addition-fragmentation agent Group of inventions refers to dentistry and concerns a dental composition, and a method for using it. The dental composition contains an addition-fragmentation agent of formula (I): wherein each R1, R2 and R3 independently means Zm-Q-, (hetero)alkyl group or (hetero)aryl group provided at least two of R1, R2 and R3 represent Zm-Q-; Q represents a binding group having a valence number m+1; Z represents ethylene-unsaturated polimerised group; m means 1-6; each X1 independently represents -O- or -NR4-, wherein R4 represents H or C1-C4alkyl; and n means 0 or 1; at least one monomer containing at least two ethylene-unsaturated groups; and an inorganic oxide excipient. A method of processing a tooth surface involves applying the above composition on the tooth surface in the individual's mouth, and hardening the above composition. |
|
Pharmaceutical composition containing glp-1 agonist and methionine Group of inventions discloses a liquid composition containing GLP-1 agonist and/or its pharmaceutically acceptable salt and differing by the fact that the composition contains methionine, wherein the composition is substantially free from histidine and EDTA, and wherein the GLP-1 agonist is present in an amount of 0.01 mg/ml to 1.5 mg/ml, whereas using them for treating diabetes mellitus and obesity. |
|
Anti-cd20 antibodies and thereof application Group of inventions relates to specifically binding CD20 antibodies, which contain variable region of light chain and variable region of heavy chain, where CDR1, CDR2 and CDR3 of said variable region of light chain contain amino acid sequences SEQ ID NO: 17-19 or SEQ ID NO: 25-27 and where CDR1, CDR2 and CDR3 of said variable region of heavy chain contain amino acid sequences SEQ ID NO: 20-22 or SEQ ID NO: 28-30, their conjugates with cytotoxic agents, as well as to their application in treatment of autoimmune and inflammatory diseases, and malignant neoplasms. |
|
Lipstick and method of its preparation Invention is a lipstick comprising an ink paste containing one or more dry pigments and coconut alkanes containing volatile oil composition, having from 50 to 100% by weight of a mixture of linear paraffins, which comprise from 70 to 99% by weight, at least one linear paraffin selected from paraffins C5, C10, C12 and their mixtures; coconut gel containing vegetable oil, Cocos Nucifera oil, styrene/butadiene copolymer, and polyethylene; and polyethylene, caprylyl glycol and the mixture of green wattle (Acacia Decurrens)/jojoba/wax of sunflower seed/polyglyceryl-3 ether in concentrations effective for ensuring melting and homogeneity of coconut alkanes. |
|
Method for prolonging youth and achieving active longevity Method for prolonging youth or achieving active longevity involves using complex herbal medicines, such as Pletnev's drops, Pletnev's drops No. 4, Pletnev's drops No. 5 and Pletnev's drops No. 30 administered per os in a dose of 2-7 drops before meals according to the following regimen: on the 1st day - Pletnev's drops No. 5 in the morning, Pletnev's drops in the evening; on the 2nd day - Pletnev's drops No. 30 in the morning, Pletnev's drops No. 4 in the evening. |
|
Method for obtaining n-acetylglucosaminyl-n-acetylmuramyl-l-alanyl-d-glutamic acid Method for obtaining N-acetylglucosaminyl-N-acetylmuramyl-L-alanyl-D-glutamic acid includes condensation of unprotected derivative of muramic acid with protected linear dipeptide, catalytic hydrogenolysis of synthesised dibenzyl ether of N-acetylglucosaminyl-N-acetylmuramyl-L-alanyl-D-glutamic acid (DBE), carried out over palladium catalyst, which is characterized by the fact that catalystic hydogenolysis is realised in ethyl alcohol medium with application of catalyst promoter - hydrazine hydrate (HH) and reducer - formic acid (FC) with the following ratio of reagents: ratio by weight {DBE:Pd} = {1:0.100-0.500}; ratio in weight percent {Pd:HH} = {100:0.5-1.5}; ratio in molar equivalents {DBE:FC} = {1:2-4}. |
|
Preparation, containing amino acids and plants, and its activity in alcohol detoxication Invention relates to pharmaceutical industry, namely to preparation for protection against chemical liver injury, increase of resistance to hypoxia, acceleration of ethanol removal in vivo and increase of ability to recovery and survival under conditions of absence of oxygen. Preparation for protection against chemical liver injury, increase of resistance to hypoxia, acceleration of ethanol removal in vivo and increase of ability to recovery and survival under conditions of absence of oxygen, which contains combination of composition (a), containing amino acids, including citrulline and ornithine hydrochloride; and composition (b), which contains mixture of ginseng extract, extract of ginkgo biloba leaves and silibinin extract, non-obligatorily with suitable filler, with each component being taken in specified quantity. Food preparation. Diet additive. Neutraceutic. Drink. Medication. Application of preparation for: protection against chemical liver injury, increase of resistance to hypoxia, acceleration of removal of ethanol in vivo, and increase of ability to recovery and survival under conditions of absence of oxygen. Method of treating or prevention of alcohol intoxication, chemical liver injury, increase of resistance to hypoxia, reduction of content of ethanol in vivo and increase of ability to recovery and survival under conditions of absence of oxygen. |
|
Silicon-containing biologically degradable material for pro-angiogenic therapy Invention refers to medicine. Described is a silicon-containing biologically degradable material for preventing and/or treating diseases, which are accompanied by low and/or disturbed angiogenesis, and/or diseases, a recovery of which requires an increase in angiogenesis. |
|
Adhesive acidic cleaning and flavouring substance for plumbing fixtures Invention relates to field of sanitary and is intended for cleaning plumbing fixtures. Substance for cleaning plumbing fixtures is capable of direct application on a plumbing fixture, adhering to it, as well as is capable of free washing off only after a large number of washing off operations. Said substance includes surface-active substances (SAS) and at least one adhesion intensifier, representing oxoacid of the following formula: |
|
Group of the inventions relates to field of methods and means for reduction of quantity of volatile sulphur-containing compounds, selected from the group, consisting of hydrogen sulphide, dimethylsulphide and methylmercaptane, by application of oral composition, containing effective quantity of combination of zinc lactate and isothiocyanate, containing at least 80% of allylisothiocyanate. |
|
Method of treating localised scleroderma Method involves correcting the pro- and antioxidant systems by prescribing the preparation Cytoflavin and performing a local exposure generated by Ultratone apparatus with the following parameters: output voltage 3.0 kV, sine-wave output voltage frequency 22 kHz. Cytoflavin is supposed to administer twice a day - in the morning and evening, not later than 5 p.m., at 8-10 hours intervals, at least 30 min before a meal, swallowing it whole and washing down with water, in a standard dosage of 760 mg; the first administration is suggested 3-4 hours before a daily session of the Ultratone therapy in a mode of 22 kHz at a distance from the affected area of 1-2 mm through a gauze wipe for 10-20 seconds per 1 cm2 of the affected area; the above treatment is accompanied with administering prednisolone in an average daily dose of 30 mg daily; repeated therapeutic courses are prescribed for indications 25-30 days later. |
|
Method involves a local intermittent exposure of the involved area to a silver preparation to initiate ion emission from its surface. Pure coin silver (assay value 999) is used as the above silver preparation. The exposure is conducted for 25-30 minutes once a day for 7-14 days. |
|
Method for obtaining auxin nanocapsules Invention relates to method for obtaining auxin nanocapsules. Said method is characterised by the fact that auxin is added into suspension of carrageenan in butanol in presence of glycerol ester with one-two molecules of food fatty acids and one-two molecules of citric acid with mixing, with further addition by pouring of 1,2-dichloroethane, obtained suspension of nanocapsules is filtered and dried at room temperature, with ratio core/envelope in nanocapsules constituting 1:1 or 5:1. |
|
Method of production of nanocapsules of gibberellic acid Method of production of nanocapsules of gibberellic acid. According to the method of the invention, gibberellic acid is added to a suspension of carrageenan in butanol in the presence of the drug E472c under stirring at 1300 rps. Butyl chloride is then added. The resulting suspension is filtered and dried at room temperature. |
|
Method for prevention of allergodermatoses Invention relates to medicine, namely dermatology and allergology, and can be used for prevention of allergodermatoses and their recurrences. For this purpose collection of allergic history is carried out and filling of allergy passport of individual is started from the moment of child birth in maternity hospital with registration of child's and mother's health condition, their predisposition to allergic processes by results of injections and laboratory parameters, obtained in case of presence of indications in carrying out immunological and allergological tests, which are further carried out with additional selection of both anaesthetics before each surgery and antibiotics before antibiotic therapy. In order to prevent development of allergic conditions and their recurrences, as well as side effect of medications in the process of treatment of various diseases subcutaneous injections of histaglobulin are performed to child in accordance with indications, and to mother with complicated allergological anamnesis 1 time per week according to the scheme - 0.2-0.4-0.6-0.8-1.0-1.2-1.4-1.6-1.8-2.0 ml, with No. 10 course at the background of hypoallergic diet, intake of enterosorbents and moderate physical exercise. |
|
|
Method of production of nanocapsules of ferrocene Invention relates to a method of encapsulation of the drug by the method of non-solvent addition, characterised in that the nuclei of the nanocapsules are used as ferrocene, the shells - as carrageenan, at that ferrocene is added slowly to the suspension of carrageenan in butanol in the presence of a surfactant E472c while stirring at 1200 rps, then hexane is poured, the resulting suspension is filtered and dried at room temperature. |
|
|
Method of production of nanocapsules of antibiotics in agar-agar Antibiotic powder is added to a suspension of agar-agar in hexane and compound ether of glycerol with one or two molecules of edible fatty acids and one or two molecules of citric acid, and then benzene is poured dropwise, the resulting suspension of nanocapsules is filtered and dried. |
|
Method for obtaining nanocapsules of quercetin or dihydroquercetin in gellan gum Quercetin or dihydroquercetin is added to suspension of gellan gum in hexane in presence of glycerol ester with one-two molecules of food fatty acids and one-two molecules of citric acid, after that butylchloride is added by pouring, obtained suspension of nanocapules is filtered and dried, with ratio core/envelope in nanocapsules constituting 1:3. |
![4,6-di(3,12-diaza-6,9-diazoniadispiro[5,2,5,2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride hydrochloride hexahydarate for treating herpetic infection, pharmaceutical composition for local application](http://img.russianpatents.com/img_data/1232/12322989-s.jpg)
|
Invention refers to medicine and represents a pharmaceutical composition in the form of a cream or gel for treating a herpes viral infection, containing 4,6-di(3,12-diaza-6,9-diazoniadispiro[5,2,5,2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride dihydrochloride hexahydrate. The invention consists in a method of treating or preventing a herpetic infection in a human or animal. |
Another patent 2551196.